AVEO Pharmaceuticals, Inc.
The earnings season is in full swing and investors are flooded with fundamental information to reassess their investments. While fundamental information should be a basic component for any investment decision, it becomes irrelevant in the biotechnology industry. The companies in this sector are usually involved in development of candidates without much topline or bottom line information. The trades by institutions and insiders are a more effective way for potential investors more »
In developing cancer treatment, one of the approaches used is to prevent blood supply to the tumor. Without their own blood supply, tumors cannot nourish themselves and grow. Being able to block blood flow to the tumor is not only an effective way to go about trying to treat cancer, but also to make it more manageable as a chronic illness at least.
Angiogenesis inhibitors are ways to indirectly kill more »
The biotechnology industry is a volatile one with some of the riskier investments on the stock market. However, many biotechnology investors would argue that sky high returns that small biotechnology companies offer ensure they are worth the high risk. The following three companies are interesting biotechnology bets, both due to prospects of capital appreciation and acquisition prospects.
AVEO Pharmaceuticals (NASDAQ: AVEO)
AVEO is a biopharmaceutical company focused on discovery, development more »
The biotechnology industry is a pretty volatile industry and has some of the riskier investments on the stock market. However many biotechnology investors would argue that sky high returns that small biotechnology companies offer ensure they are worth the high risk. The following three companies are interesting biotechnology bets both due to prospects of capital appreciation and acquisition prospects.
Aveo Pharma (NASDAQ:AVEO)
Aveo Oncology is a biopharmaceutical company focuses more »
Onyx Pharmaceuticals (NASDAQ: ONXX) is trying to shrug off its dependency on partners, and transform itself from a royalty and drug-development company into a full-fledged biopharmaceutical company. This was evident when the company’s CEO, N. Anthony Coles, said at an investors meet that, "The way to build a successful, sustainable business is through acquisitions, either companies or products -- even licensing deals."
Onyx’s CEO has things going for him more »
Several drugs that could be used to treat cancer patients are slated for approval by the U.S. Food and Drug Administration (FDA) during the first half of the year. Some of the manufacturers of these treatments are touting the medicines as being the next break through in treating the various forms of the deadly disease. This gives them the chance to continue to expand their presence in the multi-billion more »
The Baupost Group, managed by value investor Seth Klarman (author of Margin of Safety), is one of the largest hedge funds in the world. It invests in a range of industries, but in the fund’s 13F filing for the second quarter of 2012 we noticed a number of healthcare companies in prime positions in its portfolio (see other stocks the Baupost Group owns). It can be difficult to evaluate more »
What: AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) a biotech company that recently took a stock hit when the FDA expressed a desire to further examine study results of the company’s newest therapy, Tivozanib, a treatment for patients with renal cell carcinoma (RCC). The valuation was over $17 at the beginning of the year and is now down to $9.44 although the price has come up in recent days. AVEO more »
By George S. Mack, The Life Sciences Report
For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.
Imagine a novel discovery or even a novel platform that just fizzles. To a technology freak like me that sounds so disappointing to think that you can actually discover breakthrough ideas that are not disruptive and don't really change much. I recently spoke more »